Palavras-chave
Vacina
Resposta imunológica
Citocinas
SARS-CoV-2
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Avaliar o perfil imunológico de linfócitos T e B e citocinas em profissionais de saúde antes e após a vacinação contra a COVID-19. Métodos: Vinte indivíduos saudáveis, que trabalhavam na testagem de COVID-19, foram avaliados com coletas de sangue em seis momentos (T0 a T5). Os níveis de IgG contra SARS-CoV-2 e das interleucinas IL-6, IFN-γ e IL-10 foram medidos por ELISA. A imunofenotipagem de linfócitos foi realizada com anticorpos anti-CD3, anti-CD4 e anti-CD19 via citometria de fluxo (p ≤ 0,05). Resultados: Todos os participantes foram infectados por COVID-19 durante o estudo, e a maioria foi vacinada com CoronaVac e Pfizer. Em T0, 25% apresentavam IgG positivo, atingindo 100% em T3 e T5. As citocinas não variaram significativamente, mas os linfócitos TCD3+ reduziram entre T0 e T3 e T2 e T3. Observou-se diferença em TCD4+ entre T4 e T5 e variação em linfócitos B entre T0 e T5. Conclusão: A presença de IgG em T0 sugeriu exposição prévia ao vírus. Embora as citocinas não tenham mostrado variação significativa, a análise dos linfócitos T e B evidenciou mudanças imunológicas ao longo da vacinação, indicando um efeito modulador no sistema imunológico.
Referências
BAHRINI K, et al. Immune Cell Response during COVID-19 Infection and following SARS-CoV-2 Vaccination in Patients Admitted to Intensive Care Unit. J Immunol Res. 2023;2023.
BAROUCH DH. Covid-19 vaccines—immunity, variants, boosters. N Engl J Med. 2022;387(11):1011–20.
CHEN S, et al. The role of B cells in COVID-19 infection and vaccination. Front Immunol., 2022; 13: 988536.
DEB B, et al. Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials. J Biosci. 2020;45:1–10.
FAMILIAR-MACEDO D, et al. Inflammatory and cytotoxic mediators in COVID-19 patients and in ChAdOx1 nCoV-19 (AZD1222) vaccine recipients. Cytokine. 2023;171:156350.
FIDLER S, et al. Booster vaccination against SARS-CoV-2 induces potent immune responses in people with human immunodeficiency virus. Clin Infect Dis. 2023;76(2):201–9.
HAVERVALL S, et al. Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time. Clin Transl Immunol. 2022;11(4).
HE F, et al. Coronavirus disease 2019: What we know? J Med Virol. 2020;92(7):719–25.
ISLAS-VAZQUEZ L, et al. Effector-memory B-lymphocytes and follicular helper T-lymphocytes as central players in the immune response in vaccinated and nonvaccinated populations against SARS-CoV-2. Vaccines (Basel). 2022;10(10):1761.
LI Q, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020;382(13):1199–207.
LI Z, et al. Characterization of SARS-CoV-2-Specific humoral and cellular immune responses induced by inactivated COVID-19 vaccines in a real-world setting. Front Immunol. 2021;12:802858.
MACIEL E, et al. The SARS-CoV-2 vaccination campaign in Brazil and the invisibility of science evidences. Cien Saude Colet. 2022;27:951–6.
MANSOURABADI AH, et al. B lymphocytes in COVID-19: a tale of harmony and discordance. Arch Virol. 2023;168(5):148.
MINISTÉRIO DA SAÚDE. 11 Edição, Brasília. 2021. Plano Nacional de Operacionalização da Vacinação contra COVID-19.
MIRNIA K, et al. Short-term side effects of COVID-19 vaccines among healthcare workers: a multicenter study in Iran. Sci Rep. 2024;14(1):4086.
MOLLARASOULI F, et al. A review on coronavirus disease 2019 (COVID-19): current progress, clinical features and bioanalytical diagnostic methods. Microchim Acta. 2022;189(3):103.
NERY GB, et al. Impact of social distancing from the COVID-19 pandemic on the immuno-inflammatory response of older adults. BMC Geriatr. 2024;24(1):99.
NUÑEZ NG, et al. High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity. Nat Immunol. 2023;24(6):941–54.
SHEHATA AA, et al. Diversity of coronaviruses with particular attention to the interspecies transmission of SARS-CoV-2. Animals. 2022;12(3):378.
SINAEI R, et al. Short-term Safety of Covaxin, Sinopharm, Sputnik V, and AstraZeneca COVID-19 Vaccines Among Iranian Healthcare Workers: A Cross-Sectional Study. Arch Clin Infect Dis. 2024;19(1).
SOUZA-SILVA GADE, et al. Memory elicitation, T-cell response and antibody production: an independent study of an inactivated entire virus vaccine (Coronavac). An Acad Bras Cienc. 2022;94.
V’KOVSKI P, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155–70.
STRUKCINSKIENE B, et al. Immune Response to COVID-19 Vaccination in Frontline Healthcare Workers. Vaccines. 2024;12(2):199.
DORIA-ROSE N, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med. 2021;384(23):2259–61.
WORLD HEALTH ORGANIZATION. WHO COVID-19 Dashboard. Geneva: World Health Organization; 2020.
ZALEWSKA M, et al. An immune response to heterologous ChAdOx1/BNT162b2 vaccination against COVID-19: evaluation of the anti-RBD specific IgG antibodies titers and interferon gamma release assay (IGRA) test results. Vaccines (Basel). 2022;10(9):1546.
NISHIYAMA T, et al. Modeling COVID-19 vaccine booster-elicited antibody response and impact of infection history. Vaccine. 2023;41(52):7655–62.
MATSUMOTO N, et al. Longitudinal antibody dynamics after COVID-19 vaccine boosters based on prior infection status and booster doses. Sci Rep. 2024;14(1):4564.
PERICO L, et al. Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose. Front Immunol. 2023;14:1123158.
DOHERTY INSTITUTE. New analysis predicts how well vaccines will work against COVID-19 strains. 2023. Disponível em: https://www.doherty.edu.au/news-events/news/new-analysis-predicts-how-well-vaccines-will-work-against-covid-19-strains-. Acessado em: 6 fev. 2025.
NOTARTE KI, et al. Age, sex and previous comorbidities as risk factors not associated with SARS-CoV-2 infection for long COVID-19: a systematic review and meta-analysis. J Clin Med. 2022;11(24):7314.